Oxaliplatin: a review of approved uses

A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07

(2017) N. Wolmark et al.   JOURNAL OF CLINICAL ONCOLOGY

AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer.

(2017) A. De Gramont et al.   JOURNAL OF CLINICAL ONCOLOGY

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection

(2011) R. Wong et al.   ANNALS OF ONCOLOGY

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

(2011) C. Bokemeyer et al.   ANNALS OF ONCOLOGY

Antiepidermal growth factor receptor radiosensitizers in rectal cancer

(2011) Robert Glynne-Jones et al.   ANTI-CANCER DRUGS

Oxaliplatin: a review in the era of molecularly targeted therapy

(2011) T. Alcindor et al.   Current Oncology

Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis

(2011) Francesco Montagnani et al.   Gastric Cancer

Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses

(2011) Greg Yothers et al.   JOURNAL OF CLINICAL ONCOLOGY

Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer

(2011) Daniel G. Haller et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

(2011) Carlo Aschele et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

(2011) Matthew T Seymour et al.   LANCET

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

(2011) Timothy S Maughan et al.   LANCET

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

(2011) Richard A Adams et al.   LANCET ONCOLOGY

Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment

(2010) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up

(2010) R. Labianca et al.   ANNALS OF ONCOLOGY

Oxaliplatin in First-line Therapy for Advanced Non–Small-Cell Lung Cancer

(2010) Luis E. Raez et al.   Clinical Lung Cancer

Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection

(2010) Massimiliano Berretta et al.   CURRENT HIV RESEARCH

Estimates of cancer incidence and mortality in Europe in 2008

(2010) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer

(2010) Michel Ducreux et al.   INTERNATIONAL JOURNAL OF CANCER

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Entering My Final Year As Editor-in-Chief of Journal of Clinical Oncology

(2010) Daniel G. Haller   JOURNAL OF CLINICAL ONCOLOGY

Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66

(2010) Steven R. Alberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2

(2010) Jean-Pierre Gérard et al.   JOURNAL OF CLINICAL ONCOLOGY

Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7

(2010) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

(2010) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Colorectal cancer

(2010) David Cunningham et al.   LANCET

Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975

(2009) C. La Vecchia et al.   ANNALS OF ONCOLOGY

Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study

(2009) Benoist Chibaudel et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

(2009) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of transcription by platinum antitumor compounds

(2009) Ryan C. Todd et al.   Metallomics

Immunogenic death of colon cancer cells treated with oxaliplatin

(2009) A Tesniere et al.   ONCOGENE

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation

(2008) D Balin-Gauthier et al.   BRITISH JOURNAL OF CANCER

Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma

(2008) Daniel G. Haller et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials

(2008) Hendrik-Tobias Arkenau et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

(2008) Jim Cassidy et al.   JOURNAL OF CLINICAL ONCOLOGY

Oxaliplatin-Related Neurotoxicity: Interest of Calcium-Magnesium Infusion and No Impact on Its Efficacy

(2008) Laurence Gamelin et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer

(2008) Brigit Gruenberger et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

(2008) Carsten Bokemeyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

(2008) Bernard Nordlinger et al.   LANCET